MACROGENICS INC cotiza a 3.72 USD y tiene una capitalización bursátil de $237M. En los últimos 12 meses ha facturado $168M con un margen de flujo de caja libre del -55.5%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and …
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-03 |
|---|---|---|---|---|
| Real | — | — | $-0.58 | $-0.22 |
| Estimado | $-0.13 | $0.26 | $-0.55 | $-0.02 |
| Sorpresa | — | — | -5.5% | -1000.0% |
| Métrica | MGNX | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 100.0% | 57.0% | +43.0% |
| Operating Margin | -48.7% | -38.6% | -10.1% |
| Net Margin | -49.9% | -33.6% | -16.3% |
| FCF Margin | -55.5% | -13.9% | -41.6% |
| ROE | -134.2% | -40.4% | -93.8% |
| ROA | -29.1% | -32.0% | +3.0% |
| Current Ratio | 5.10 | 2.84 | +2.26 |
| Debt / Equity | — | 0.28 | — |